Learning Objectives:

To discuss the benefits and drawbacks of Mepolizumab in the treatment of EOE.
To determine whether mepolizumab was more effective than placebo for improving symptoms of dysphagia.
To understand if Mepolizumab treatment has any effect on the absolute peak eosinophil count and to understand histologic response after 3 months of treatment.
 

Session date: 
01/28/2026 - 11:00am to 12:00pm EST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
    Children’s National Hospital designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
    Successful completion of this continuing education activity.
Please login or register to take this course.
Faculty List: 
Speaker(s)

Anusha Rao

has no relevant financial relationships to disclose at this time.